Developmental Research Program

发展研究计划

• 批准号: 10494111
• 负责人: KEVIN M. SHANNON
• 金额: $ 9.39万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10494111
• 关键词: Acceleration; Address; Advanced Malignant Neoplasm; Applications Grants; Area; Basic Science; California; Cancer Center; Clinical; Clinical Sciences; Collaborations; Communities; Country; Data; Department of Defense; Development; Diagnosis; Discipline; Disease; Early treatment; Evaluation; Funding; Funding Agency; Goals; Health Sciences; Human; Human Development; Indiana; Institution; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mission; NF1 gene; NF1 mutation; National Cancer Institute; Neurofibromatoses; Pediatric Hospitals; Pediatric Oncology; Philadelphia; Pilot Projects; Population Sciences; Predisposition; Process; Research; Research Activity; Research Personnel; Research Project Grants; Resources; San Francisco; Scientist; Senior Scientist; Sex Orientation; Signal Transduction; Syndrome; Talents; Techniques; Texas; Therapeutic; Translational Research; Tumor stage; Underrepresented Minority; Underrepresented Populations; United States National Institutes of Health; Universities; Work; anticancer research; base; career; disability; effective therapy; expectation; faculty support; high reward; high risk; hyperactive Ras; improved; innovation; minority investigator; neoplasm therapy; professor; programs; racial and ethnic; recruit; translational cancer research; translational study; tumor

ABSTRACT – DEVELOPMENTAL REARCH PROGRAM The DHART SPORE Developmental Research Program (DRP) will support innovative pilot projects to advance the diagnosis and treatment of early stage tumors and advanced cancers characterized by germline and somatic NF1 mutations. The DRP will accomplish this goal by supporting rigorous translational research in the areas of population science, therapeutics, and mechanisms of disease. We expect that many established investigators will utilize DRP support to launch new research endeavors and to generate preliminary data in NF1 and RASopathy-associated cancers leading to successful grant applications to the NIH, the Department of Defense NF Research Program, and other funding agencies. The ultimate goal of the DRP is to advance high level research activities related to NF1-associated tumors, which we will achieve by recruiting and supporting established investigators developing a new research theme in the field of NF1-related cancers. The translational studies supported by the DRP also have the potential to replace SPORE projects that have been completed or are not progressing satisfactorily toward achieving their objectives. This SPORE also includes a Career Enhancement Program (CEP) for young investigators, which is described in a separate section of this application. The institutions participating in the DHART SPORE renewal have committed a total of $1.65 million to support the Developmental Programs of the DHART SPORE (inclusive of the DRP and CEP). Investigators from any DHART SPORE center can apply for DRP funds. In addition, we actively solicit applications from non-SPORE investigators and institutions. The specific aims of the DRP are: (1) to fund promising projects in order to generate preliminary data for grant applications to the NIH or other federal funding agencies. The DRP emphasizes supporting the recruitment of investigators from historically disenfranchised racial, ethnic, sexual orientation and disability groups that are under-represented in health sciences, hereafter termed underrepresented minority (URM) investigators ; (2) to support the development of new techniques and resources that can be applied to advance translational research to improve the treatment of NF1-associated tumors; (3) to expand the scope of research in NF1, including funding high risk/high reward projects; and, (4) to recruit talented investigators into NF1 research as it relates to cancer, and to promote new collaborations in this field across a range of investigators and disciplines. The DRP will provide evaluation, funding, and oversight for pilot projects. Each project will receive a minimum of $50,000 with a maximum of $75,000 per year, with the potential for a single renewal. Applications for DRP support (including requests for a second year of funding) will be evaluated through a competitive process with review by a Developmental Programs Steering Committee (DPSC) comprised of senior scientists participating in this SPORE and oversight and guidance from the External and Internal Advisory Boards.

抽象发展型研究程序 DHART孢子发展研究计划(DRP)将支持创新的先导项目 早期肿瘤和晚期肿瘤的诊断和治疗 体细胞NF1突变。DRP将通过支持严格的翻译研究在 人口科学、治疗学和疾病机制的领域。我们预计，许多已建立的 调查人员将利用DRP的支持来启动新的研究努力，并在 NF1和类风湿相关癌症导致NIH成功申请拨款，卫生部 国防核子研究计划和其他资助机构。民主同盟党的最终目标是推进 与NF1相关肿瘤相关的高水平研究活动，我们将通过招募和 支持现有研究人员在NF1相关癌症领域开发新的研究主题。这个 由DRP支持的翻译研究也有可能取代已经被 完成或没有令人满意地实现他们的目标。该孢子还包括一个 针对年轻调查人员的职业提升计划(CEP)，在本部分的单独部分中进行了介绍 申请。参与DHART孢子更新的机构共承诺拨款1.65元。 支持DHART孢子发展项目(包括DRP和CEP)100万美元。 任何DHART孢子中心的调查人员都可以申请DRP资金。此外，我们还积极征集 来自非孢子调查人员和机构的申请。DRP的具体目标是：(1)资助 有前景的项目，以便为NIH或其他联邦政府的拨款申请生成初步数据 资助机构。民进党强调支持从历史上招募调查人员 被剥夺选举权的种族、族裔、性取向和残疾群体在健康方面的代表性不足 科学，以下称为代表不足的少数群体(URM)调查员；(2)支持发展 可应用于促进转化研究以改善治疗的新技术和资源 NF1相关肿瘤的研究；(3)扩大NF1的研究范围，包括资助高风险/高回报 项目；以及，(4)招募有才华的研究人员参与与癌症有关的NF1研究，并推动新的 在这一领域的合作涉及一系列研究人员和学科。DRP将提供评估， 为试点项目提供资金和监督。每个项目将获得最低50,000美元，最高为 每年75,000美元，有可能续签一次。DRP支持申请(包括申请 资金的第二年)将通过竞争性程序进行评估，并由开发人员进行审查 项目指导委员会(DPSC)由参加该项目的资深科学家和 外部和内部咨询委员会的监督和指导。